Hi NZ Trader Agree it should be corrected but tried last year to...

Hi NZ Trader

Agree it should be corrected but tried last year to contact company on a minor personal issue and had no success.  Happy for anyone who has an ear that will listen to bring it to Immuron's attention.

On a side note I just read another poster who was suggesting that the quality of yesterdays announcement was wanting so he too is probably being influenced by this poorly undertaken research particularly when the head researcher  Professor Sanyal is quoted as stating:

"This is truly a proof of concept for this first-in-class drug candidate." said Arun Sanyal, Professor of Gastroenterology and Hepatology from the Virginia Commonwealth University in Richmond, USA and the study lead Principle Investigator.

"The IMM-124E drug candidate has been developed to target LPS in the gut and prevent it translocating into the portal circulation. The study results clearly demonstrate a statistically significant reduction of serum LPS levels in the treatment groups when compared to placebo and provides us with a proof of concept that metabolic endotoxemia can indeed be decreased using this drug candidate (IMM-124E) which targets the endotoxin LPS. We are encouraged that IMM-124E, a drug with an exceptional safety profile, can lower the LPS-associated inflammatory burden and improve liver enzymes. The potential clinical applications for this drug candidate are numerous and very exciting indeed"